This article is part of the supplement: Severe sepsis and drotrecogin alfa (activated)
The protein C pathway: implications for the design of the RESPOND study
-
* Corresponding author: Burkhard Vangerow vangerow_burkhard@lilly.com
Critical Care 2007, 11(Suppl 5):S4 doi:10.1186/cc6155
Accesses
- Last 30 days: 68 accesses
- Last year: 465 accesses
- All time: 3948 accesses
Cited by
BioMed Central: 4 citations
|
Research
Andrew F Shorr, Jonathan M Janes, Antonio Artigas, Jyrki Tenhunen, Duncan LA Wyncoll, Emmanuelle Mercier, Bruno Francois, Jean-Louis Vincent, Burkhard Vangerow, Darell Heiselman, Amy G Leishman, Yajun E Zhu, Konrad Reinhart, Critical Care 2010, 14:R229 (21 December 2010) |
|
Commentary
Protein C as a surrogate end-point for clinical trials of sepsis Kathleen D Liu, Michael A Matthay Critical Care 2008, 12:139 (24 April 2008) |
|
Review
Recombinant human activated protein C: current insights into its mechanism of action Marcel Levi, Tom van der Poll Critical Care 2007, 11(Suppl 5):S3 (19 December 2007) |
|
Introduction
Introduction: severe sepsis and drotrecogin alfa (activated) Antonio Artigas, Claude D Martin Critical Care 2007, 11(Suppl 5):S1 (19 December 2007) |